血府逐瘀胶囊联合N-乙酰半胱氨酸治疗特发性肺纤维化临床观察

发布时间：2018-04-24 06:18

本文选题：特发性肺纤维化 + 血府逐瘀胶囊　；参考：《中华中医药杂志》2015年02期

【摘要】：目的:观察血府逐瘀胶囊联合N-乙酰半胱氨酸抑制特发性肺纤维化(IPF)进展的有效性和安全性。方法:选择临床诊断IPF患者40例,随机分为治疗组(20例)和对照组(20例),两组均予N-乙酰半胱氨酸口服,1片/次,2次/d,治疗组联合血府逐瘀胶囊口服,5粒/次,2次/d,均治疗18个月,评价疾病无进展生存(PFS)率和时间、IPF急性加重(AE-IPF)发生率、肺功能(TLC、FVC、DLCO)、6MWT(距离、6MWT前/后Sp O2)、Borg评分与基线水平差值。结果:完成研究34例(治疗组18例、对照组16例),治疗组PFS率(77.8%)高于对照组(50.0%),治疗组PFS时间(16.70个月)高于对照组(14.16个月),差异无统计学意义;治疗组AEIPF发生率(5.6%)低于对照组(12.5%),差异无统计学意义;治疗组TLC、FVC、DLCO降低值均低于对照组,差异无统计学意义,治疗组6MWT距离、6MWT后Sp O2降低值均低于对照组,差异有统计学意义(P0.05),治疗组6MWT前Sp O2降低值低于对照组,差异无统计学意义,治疗组Borg评分降低值低于对照组,差异有统计学意义(P0.05)。治疗组不良反应发生率(11.11%)高于对照组(6.25%),差异无统计学意义。结论:联合治疗有减少IPF疾病进展和急性加重次数的趋势,可减缓肺功能和运动耐量下降速度。
[Abstract]:Aim: to observe the efficacy and safety of Xuefu Zhuyu capsule combined with N-acetylcysteine in inhibiting the progression of idiopathic pulmonary fibrosis (IPF). Methods: 40 patients with IPF were selected. Two groups were randomly divided into treatment group (n = 20) and control group (n = 20). Both groups were treated with N- acetylcysteine orally for 2 times a day, and the treatment group combined with Xuefu Zhuyu capsule for two times a day for 18 months. The PFSs rate and time of acute exacerbation of IPF were evaluated, and the difference between the baseline level and the lung function of TLCFV / DLCOC / 6MWTwas evaluated. Results: 34 cases (18 cases in the treatment group and 16 cases in the control group) completed the study. The PFS rate of the treatment group was 77.8% higher than that of the control group (50.0%). The PFS time of the treatment group (16.70 months) was higher than that of the control group (14.16 months), and the difference was not statistically significant. The incidence of AEIPF in the treatment group (5.6m) was lower than that in the control group (12.5MWT), the difference was not statistically significant (P < 0.05), the decrease value of AEIPF in the treatment group was lower than that in the control group (P < 0.01), and the decrease value of SPO _ 2 in the treatment group was lower than that in the control group after 6MWT distance was 6MWT. The difference was statistically significant (P 0.05). The decrease of SPO 2 before 6MWT in the treatment group was lower than that in the control group, but the difference was not statistically significant. The Borg score in the treatment group was lower than that in the control group, and the difference was statistically significant (P 0.05). The incidence of adverse reactions in treatment group (11.11) was higher than that in control group (6.25%). Conclusion: combined therapy has a tendency to reduce the progression and acute exacerbation of IPF, and can slow down the decline of pulmonary function and exercise tolerance.
【作者单位】：天津中医药大学第一附属医院;
【分类号】：R563.9

【参考文献】